Biohaven Ltd. (NYSE:BHVN) — Market Cap & Net Worth
Market Cap & Net Worth: Biohaven Ltd. (BHVN)
Biohaven Ltd. (NYSE:BHVN) has a market capitalization of $1.80 Billion ($1.80 Billion) as of October 10, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #6469 globally and #2031 in its home market, demonstrating a -10.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biohaven Ltd.'s stock price $11.93 by its total outstanding shares 150560990 (150.56 Million).
Biohaven Ltd. Market Cap History: 2022 to 2026
Biohaven Ltd.'s market capitalization history from 2022 to 2026. Data shows growth from $2.09 Billion to $1.80 Billion (12.91% CAGR). Check Biohaven Ltd. share price for real-time trading data and today's change.
Biohaven Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biohaven Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see BHVN cash generation efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BHVN by Market Capitalization
Companies near Biohaven Ltd. in the global market cap rankings as of October 10, 2026. See net asset quality index of Biohaven Ltd. to understand what proportion of total assets are financed by equity.
Key companies related to Biohaven Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $127.55 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $74.80 Billion USD.
- CSL Ltd (AU:CSL): Ranked #450 globally with a market cap of $62.29 Billion USD ( AU$88.04 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $127.55 Billion | $503.25 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $739.57 |
| #450 | CSL Ltd | AU:CSL | $62.29 Billion | AU$181.46 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $197.00 |
Biohaven Ltd. Historical Marketcap From 2022 to 2026
Between 2022 and today, Biohaven Ltd.'s market cap moved from $2.09 Billion to $ 1.80 Billion, with a yearly change of 12.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.80 Billion | +5.67% |
| 2025 | $1.70 Billion | -69.77% |
| 2024 | $5.62 Billion | -12.73% |
| 2023 | $6.44 Billion | +208.36% |
| 2022 | $2.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 9th, 2026 the market cap of Biohaven Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.80 Billion USD |
| MoneyControl | $1.80 Billion USD |
| MarketWatch | $1.80 Billion USD |
| marketcap.company | $1.80 Billion USD |
| Reuters | $1.80 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase… Read more